Music interventions have been widely adopted as a potential non-pharmacological therapy
for patients with Alzheimer's disease (AD) to treat cognitive and/or behavioral symptoms of …

Background: The effectiveness of the 5 US Food and Drug Administration–approved
pharmacologic therapies for dementias in achieving clinically relevant improvements is …

Pharmacologic treatments for Alzheimer's disease include the cholinesterase inhibitors
donepezil, galantamine, and rivastigmine. We reviewed their evidence by searching …

The neurotransmitter glutamate activates several classes of metabotropic receptor and three
major types of ionotropic receptor–α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid …

Objective: To systematically review the literature and summarize the effect of cognitive
training (CT) for Alzheimer's disease (AD) patients on multiple functional domains. Method …

Alzheimer's disease (AD) is the most common cause of memory impairment and dementia in
the elderly. AD is pathologically characterized by extracellular deposits of beta-amyloid (Aβ) …

Alzheimer's disease (AD) is a progressive and ultimately fatal condition that causes
debilitating memory loss and extensive deterioration of cognitive and functional abilities …

Background There is no cure for dementia, and no treatments exist to halt or reverse the
course of the disease. Treatments are aimed at improving cognitive and functional …

Sustained release nanoparticulate formulations of Rivastigmine tartrate (RT) were prepared,
optimized (using factorial design) and characterized using the biodegradable polymers …

With the aging population and its rapidly increasing prevalence, dementia has become an
important public health concern in developed and developing countries. To date, the …